Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vaccines, In Brief: Meningitis B Recommendation Limited To High-Risk Groups

This article was originally published in The Pink Sheet Daily

Executive Summary

Also, CDC advisory committee withdraws preferred status for AstraZeneca’s FluMist in children and adds Merck’s Gardasil 9 to recommendations for HPV vaccination.

You may also be interested in...



Merck’s Gardasil Adds Serotypes; Boosting Vaccinations Seems Bigger Challenge

Promotion strategy likely to remain same after nine-valent HPV vaccine wins FDA approval; Merck may need help from the CDC to overcome cultural barriers to adoption.

COVID Vaccine Boosters: US Exploring Ways To Get Immunocompromised People An Extra Dose

Dosing is capped under emergency use authorizations, but studies show reduced antibody response following primary vaccination series in individuals with compromised immune systems; although BLA approval could allow for off-label prescribing, government officials are exploring other regulatory options for earlier access, including through a study.

Cancer Trials Should Focus On Collecting Data ‘Strictly Necessary’ For Assessing Efficacy

In journal article, leaders from academia, industry, NCI and FDA propose building upon pandemic-necessitated flexibilities in clinical research, including making it easier for trial participants to access investigational drugs in their own communities and reduced reporting of uninformative adverse events.

Topics

Related Companies

UsernamePublicRestriction

Register

PS078216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel